Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Claritev ( (CTEV) ) has issued an update.
On February 23, 2026, Claritev Corporation reported fourth-quarter 2025 revenue of $246.6 million and a net loss of $80.6 million, with adjusted EBITDA of $151.3 million and strong improvements in operating cash flow and free cash flow versus the prior year. For full-year 2025, revenue rose 3.7% to $965.4 million, net loss narrowed sharply to $284.3 million from $1.65 billion, and the company processed $179.8 billion in claim charges while identifying $25.0 billion in potential medical cost savings, underscoring its role in healthcare cost containment.
Management characterized 2025 as a pivotal turnaround year marked by renewed top-line growth, record bookings, a corporate rebrand, new solutions and partnerships, and a migrated technology foundation. Looking ahead, Claritev initiated 2026 guidance with revenues of $980 million to $1 billion, modest positive free cash flow, and higher capital expenditures, and its board approved a five-year share repurchase program of up to $75 million, signaling confidence in the company’s financial trajectory and commitment to shareholder value despite ongoing net losses.
The most recent analyst rating on (CTEV) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Claritev stock, see the CTEV Stock Forecast page.
Spark’s Take on CTEV Stock
According to Spark, TipRanks’ AI Analyst, CTEV is a Neutral.
The score is held down primarily by weak financial performance (large losses, negative free cash flow, and a high-risk balance sheet with negative equity) and bearish technicals (price well below key moving averages with negative MACD). These are partially offset by a positive earnings-call outlook (raised guidance, strong renewals, ACV and pipeline growth), while valuation offers limited support due to negative earnings and no dividend yield.
To see Spark’s full report on CTEV stock, click here.
More about Claritev
Claritev Corporation is a U.S.-based healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for payers, employers, patients, providers and third parties. Leveraging multiple data sources, over 45 years of claims experience, AI and an enterprise platform, it offers solutions that drive medical cost savings, price transparency, and optimized network and benefit design.
Average Trading Volume: 195,947
Technical Sentiment Signal: Sell
Current Market Cap: $389.3M
For detailed information about CTEV stock, go to TipRanks’ Stock Analysis page.